Integrated DNA Technologies (IDT), a Danaher company, announced the expansion of its manufacturing footprint in Coralville, Iowa. The investment delivers a more than threefold increase in synthesis capacity, enabling faster, more scalable production of high‑quality, customizable oligonucleotides that support next‑generation sequencing (NGS)‑based oncology workflows, including minimal residual disease (MRD) applications.
The expansion adds new production space within IDT’s existing Coralville campus and includes the installation of additional synthesizers and high‑throughput ancillary equipment. Together, these enhancements increase manufacturing speed and flexibility while maintaining IDT’s rigorous quality and safety standards. This milestone completes the current phase of IDT’s capacity expansion, with additional investments underway to support continued future growth.
Combined with IDT’s recent expansion of R&D and innovation capabilities in Sunnyvale, Calif., the Coralville investment reinforces IDT’s end‑to‑end leadership across MRD—connecting cutting‑edge assay innovation with scalable, high‑quality manufacturing to help customers move from discovery to delivery faster.
“MRD testing has become an essential component of modern cancer research, and our customers continue to push the boundaries of innovation,” said Ajay Gannerkote, president at IDT. “This expansion reflects our ability to translate innovation into reliable, high‑quality manufacturing at scale. By combining customization, speed and consistency, we are helping customers unlock critical cancer insights faster and with greater confidence.”
The Coralville expansion is purpose‑built to support highly customized oligonucleotide solutions required for MRD and advanced oncology research. Increased synthesis capacity enables flexible customization across labeling, concentration, formulation, yield and delivery formats, allowing researchers to tailor solutions to increasingly complex assay requirements.
By optimizing its existing manufacturing footprint and production flow, IDT has significantly increased output while continuing to leverage the same proven, best‑in‑class technologies that have supported NGS innovation for more than 20 years. As part of the expansion, IDT has achieved a more than threefold increase in production capacity for oPools™ Oligo Pools, enabling rapid, flexible assay development for oncology research. The enhanced footprint also increases synthesis flexibility across IDT’s portfolio, from highly customized MRD solutions to scalable eBlocks™ workflows.
“These investments allow us to deliver competitive turnaround times without compromising the testing, quality control and manufacturing excellence our customers rely on,” Gannerkote added